The devil in the details: The emerging role of anticitrulline autoimmunity in rheumatoid arthritis

Journal of Immunology

Volumn 175, Issue 9, 2005, Pages 5575-5580

  Van Gaalen, Floris ^a   Ioan Facsinay, Andreea ^a   Huizinga, Tom W J ^a   Toes, René E M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ARGININE; AUTOANTIBODY; CITRULLINE; CITRULLINE ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PROTEIN ARGININE DEIMINASE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CATALYSIS; CHRONIC INFLAMMATION; CLINICAL FEATURE; DISEASE MODEL; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; JOINT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REACTION ANALYSIS; RHEUMATOID ARTHRITIS; SHORT SURVEY;

EID: 27144472199     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.9.5575     Document Type: Short Survey

References (64)

1. Marrack, P., J. Kappler, and B. L. Kotzin. 2001. Autoimmune disease: why and where it occurs. Nat. Med. 7: 899-905.
2. Rose, N. R., and C. Bona. 1993. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol. Today 14: 426-430.
3. Witebsky, E., N. R. Rose, K. Terplan, J. R. Paine, and R. W. Egan. 1957. Chronic thyroiditis and autoimmunization. J. Am. Med. Assoc. 164: 1439-1447.
4. Hill, J. A., S. Southwood, A. Sette, A. M. Jevnikar, D. A. Bell, and E. Cairns. 2003. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J. Immunol. 171: 538-541.
5. Borza, D. B., E. G. Neilson, and B. G. Hudson. 2003. Pathogenesis of Goodpasture syndrome: a molecular perspective. Semin. Nephrol. 23: 522-531.
6. Hughes, B. W., M. L. Moro De Casillas, and H. J. Kaminski. 2004. Pathophysiology of myasthenia gravis. Semin. Neurol. 24: 21-30.
7. Ji, H., K. Ohmura, U. Mahmood, D. M. Lee, F. M. Hofhuis, S. A. Boackle, K. Takahashi, V. M. Holers, M. Walport, C. Gerard, et al. 2002. Arthritis critically dependent on innate immune system players. Immunity 16: 157-168.
8. Monach, P. A., C. Benoist, and D. Mathis. 2004. The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease. Adv. Immunol. 82: 217-248.
9. Dorner, T., K. Egerer, E. Feist, and G. R. Burmester. 2004. Rheumatoid factor revisited. Curr. Opin. Rheumatol. 16: 246-253.
10. Nienhuis, R. L., and E. Mandema. 1964. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann. Rheum. Dis. 23: 302-305.
11. Young, B. J., R. K. Mallya, R. D. Leslie, C. J. Clark, and T. J. Hamblin. 1979. Antikeratin antibodies in rheumatoid arthritis. Br. Med. J. 2: 97-99.
12. Miossec, P., P. Youinou, P. Le Goff, and M. P. Moineau. 1982. Clinical relevance of antikeratin antibodies in rheumatoid arthritis. Clin. Rheumatol. 1: 185-189.
13. Sondag-Tschroots, I. R., C. Aaij, J. W. Smit, and T. E. Feltkamp. 1979. The antiperinuclear factor. 1. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. Ann. Rheum. Dis. 38: 248-251.
14. Aho, K., R. von Essen, P. Kurki, T. Palosuo, and M. Heliovaara. 1993. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J. Rheumatol. 20: 1278-1281.
15. Vincent, C., G. Serre, F. Lapeyre, B. Fournie, C. Ayrolles, A. Fournie, and J. P. Soleilhavoup. 1989. High diagnostic value in rheumatoid arthritis of antibodies to the stratum corneum of rat oesophagus epithelium, so-called "antikeratin antibodies." Ann. Rheum. Dis. 48: 712-722.
16. Simon, M., E. Girbal, M. Sebbag, V. Gomes-Daudrix, C. Vincent, G. Salama, and G. Serre. 1993. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J. Clin. Invest. 92: 1387-1393.
17. Schellekens, G. A., B. A. de Jong, F. H. van den Hoogen, L. B. van de Putte, and W. J. van Venrooij. 1998. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 101: 273-281.
18. Girbal-Neuhauser, E., J. J. Durieux, M. Arnaud, P. Dalbon, M. Sebbag, C. Vincent, M. Simon, T. Senshu, C. Masson-Bessiere, C. Jolivet-Reynaud, et al. 1999. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J. Immunol. 162: 585-594.
19. Sebbag, M., M. Simon, C. Vincent, C. Masson-Bessiere, E. Girbal, J. J. Durieux, and G. Serre. 1995. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 95: 2672-2679.
20. Vossenaar, E. R., N. Despres, E. Lapointe, A. van der Heijden, M. Lora, T. Senshu, W. J. van Venrooij, and H. A. Menard. 2004. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res. Ther. 6: R142-R150.
21. Union, A., L. Meheus, R. L. Humbel, K. Conrad, G. Steiner, H. Moereels, H. Pottel, G. Serre, and F. De Keyser. 2002. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum. 46: 1185-1195.
22. Asaga, H., M. Yamada, and T. Senshu. 1998. Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem. Biophys. Res. Commun. 243: 641-646.
23. Tarcsa, E., L. N. Marekov, G. Mei, G. Melino, S. C. Lee, and P. M. Steinert. 1996. Protein unfolding by peptidylarginine deiminase: substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J. Biol. Chem. 271: 30709-30716.
24. Wang, Y., J. Wysocka, J. Sayegh, Y. H. Lee, J. R. Perlin, L. Leonelli, L. S. Sonbuchner, C. H. McDonald, R. G. Cook, Y. Dou, et al. 2004. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306: 279-283.
25. Cuthbert, G. L., S. Daujat, A. W. Snowden, H. Erdjument-Bromage, T. Hagiwara, M. Yamada, R. Schneider, P. D. Gregory, P. Tempst, A. J. Bannister, and T. Kouzarides. 2004. Histone deimination antagonizes arginine methylation. Cell 118: 545-553.
26. Vossenaar, E. R., A. J. Zendman, W. J. van Venrooij, and G. J. Pruijn. 2003. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25: 1106-1118.
27. Vossenaar, E. R., T. R. Radstake, A. van der Heijden, M. A. van Mansum, C. Dieteren, D. J. de Rooij, P. Barrera, A. J. Zendman, and W. J. van Venrooij. 2004. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann. Rheum. Dis. 63: 373-381.
28. Vossenaar, E. R., T. J. Smeets, M. C. Kraan, J. M. Raats, W. J. van Venrooij, and P. P. Tak. 2004. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum. 50: 3485-3494.
29. Chapuy-Regaud, S., M. Sebbag, D. Baeten, C. Clavel, C. Foulquier, F. De Keyser, and G. Serre. 2005. Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides. J. Immunol. 174: 5057-5064.
30. Masson-Bessiere, C., M. Sebbag, E. Girbal-Neuhauser, L. Nogueira, C. Vincent, T. Senshu, and G. Serre. 2001. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the α- and β-chains of fibrin. J. Immunol. 166: 4177-4184.
31. Reparon-Schuijt, C. C., W. J. van Esch, C. van Kooten, G. A. Schellekens, B. A. de Jong, W. J. van Venrooij, F. C. Breedveld, and C. L. Verweij. 2001. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum. 44: 41-47.
32. Masson-Bessiere, C., M. Sebbag, J. J. Durieux, L. Nogueira, C. Vincent, E. Girbal-Neuhauser, R. Durroux, A. Cantagrel, and G. Serre. 2000. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin. Exp. Immunol. 119: 544-552.
33. Miossec, P., P. Youinou, P. Le Goff, and M. P. Moineau. 1982. Clinical relevance of antikeratin antibodies in rheumatoid arthritis. Clin. Rheumatol. 1: 185-189.
34. Schellekens, G. A., H. Visser, B. A. de Jong, F. H. van den Hoogen, J. M. Hazes, F. C. Breedveld, and W. J. van Venrooij. 2000. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43: 155-163.
35. Wener, M. H., K. Hutchinson, C. Morishima, and D. R. Gretch. 2004. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum. 50: 2305-2308.
36. Palosuo, T., R. Tilvis, T. Strandberg, and K. Aho. 2003. Filaggrin related antibodies among the aged. Ann. Rheum. Dis. 62: 261-263.
37. Rantapaa-Dahlqvist, S., B. A. de Jong, E. Berglin, G. Hallmans, G. Wadell, H. Stenlund, U. Sundin, and W. J. van Venrooij. 2003. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48: 2741-2749.
38. Nielen, M. M., D. van Schaardenburg, H. W. Reesink, R. J. van de Stadt, I. E. van der Horst-Bruinsma, M. H. de Koning, M. R. Habibuw, J. P. Vandenbroucke, and B. A. Dijkmans. 2004. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50: 380-386.
39. van Gaalen, F. A., S. P. Linn-Rasker, W. J. van Venrooij, B. A. de Jong, F. C. Breedveld, C. L. Verweij, R. E. Toes, and T. W. Huizinga. 2004. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 50: 709-715.
40. Suzuki, A., R. Yamada, X. Chang, S. Tokuhiro, T. Sawada, M. Suzuki, M. Nagasaki, M. Nakayama-Hamada, R. Kawaida, M. Ono, et al. 2003. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34: 395-402.
41. Barton, A., J. Bowes, S. Eyre, K. Spreckley, A. Hinks, S. John, and J. Worthington. 2004. A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis Rheum. 50: 1117-1121.
42. Caponi, L., E. Petit-Teixeira, M. Sebbag, F. Bongiorni, S. Moscato, F. Pratesi, C. Pierlot, J. Osorio, S. Chapuy-Regaud, M. Guerrin, et al. 2005. A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann. Rheum. Dis. 64: 587-593.
43. Hoppe, B., G. A. Heymann, F. Tolou, H. Kiesewetter, T. Doerner, and A. Salama. 2004. High variability of peptidylarginine deiminase 4 (PADI4) in a healthy white population: characterization of six new variants of PADI4 exons 2-4 by a novel haplotype-specific sequencing-based approach. J. Mol. Med. 82: 762-767.
44. van Gaalen, F. A., J. van Aken, T. W. Huizinga, G. M. Schreuder, F. C. Breedveld, E. Zanelli, W. J. van Venrooij, C. L. Verweij, R. E. Toes, and R. R. de Vries. 2004. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum. 50: 2113-2121.
45. Zanelli, E., F. C. Breedveld, and R. R. de Vries. 2000. HLA class II association with rheumatoid arthritis: facts and interpretations. Hum. Immunol. 61: 1254-1261.
46. Vossenaar, E. R., and W. J. van Venrooij. 2004. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res. Ther. 6: 107-111.
47. Tsuji, Y., M. Akiyama, K. Arita, T. Senshu, and H. Shimizu. 2003. Changing pattern of deiminated proteins in developing human epidermis. J. Invest. Dermatol. 120: 817-822.
48. Wood, D. D., and M. A. Moscarello. 1989. The isolation, characterization, and lipid-aggregating properties of a citrulline containing myelin basic protein. J. Biol. Chem. 264: 5121-5127.
49. Vossenaar, E. R., S. Nijenhuis, M. M. Helsen, H. A. Van Der, T. Senshu, W. B. van den Berg, W. J. van Venrooij, and L. A. Joosten. 2003. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum. 48: 2489-2500.
50. Linn-Rasker, S. P., A. H. van der Helm-van Mil, F. A. van Gaalen, M. Kloppenburg, R. de Vries, S. le Cessie, F. C. Breedveld, R. E. Toes, and T. W. Huizinga. 2005. Smoking is a risk factor for anti-CCP antibodies only in RA patients that carty HLA-DRB1 shared epitope alleles. Ann. Rheum. Dis. In press.
51. Gregersen, P. K. 2005. Pathways to gene identification in rheumatoid arthritis: PTPN22 and beyond. Immunol. Rev. 204: 74-86.
52. Goedvolk, C. A., I. A. von Rosenstiel, and A. P. Bos. 2003. Immune complex associated complications in the subacute phase of meningococcal disease: incidence and literature review. Arch. Dis. Child. 88: 927-930.
53. Lawley, T. J., L. Bielory, P. Gascon, K. B. Yancey, N. S. Young, and M. M. Frank. 1984. A prospective clinical and immunologic analysis of patients with serum sickness. N. Engl. J. Med. 311: 1407-1413.
54. Nandakumar, K. S., L. Svensson, and R. Holmdahl. 2003. Collagen type II-specific monoclonal and body-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am. J. Pathol. 163: 1827-1837.
55. Kouskoff, V., A. S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis. 1996. Organ-specific disease provoked by systemic autoimmunity. Cell 87: 811-822.
56. Wipke, B. T., Z. Wang, J. Kim, T. J. McCarthy, and P. M. Allen. 2002. Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat. Immunol. 3: 366-372.
57. Wipke, B. T., Z. Wang, W. Nagengast, D. E. Reichert, and P. M. Allen. 2004. Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes. J. Immunol. 172: 7694-7702.
58. Dahlback, B. 2005. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J. Intern. Med. 257: 209-223.
59. Shi, Y., J. E. Evans, and K. L. Rock. 2003. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516-521.
60. Scaffidi, P., T. Misteli, and M. E. Bianchi. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195.
61. Savill, J. S., A. H. Wyllie, J. E. Henson, M. J. Walport, P. M. Henson, and C. Haslett. 1989. Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J. Clin. Invest. 83: 865-875.
62. Nakayama-Hamada, M., A. Suzuki, K. Kubota, T. Takazawa, M. Ohsaka, R. Kawaida, M. Ono, A. Kasuya, H. Furukawa, R. Yamada, and K. Yamamoto. 2005. Comparison of enzymatic properties between hPADI2 and hPADI4. Biochem. Biophys. Res. Commun. 327: 192-200.
63. Vincent, C., L. Nogueira, M. Sebbag, S. Chapuy-Regaud, M. Arnaud, O. Letourneur, D. Rolland, B. Fournie, A. Cantagrel, M. Jolivet, and G. Serre. 2002. Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum. 46: 2051-2058.
64. Lee, D. M., and P. H. Schur. 2003. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann. Rheum. Dis. 62: 870-874.